Enter your email address
Submit
Write your message
Volume 15, Issue 3 (Iranian Journal of Breast Diseases 2022)
ijbd 2022, 15(3): 99-111 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Talib Dawod A, Hassan Abood A. Association of P53 Immunohistochemical Expression with Other Breast Cancer Histopathological Features. ijbd 2022; 15 (3) :99-111
URL: http://ijbd.ir/article-1-967-en.html
URL: http://ijbd.ir/article-1-967-en.html
1- Faculty of Sciences, University of Kufa, Najaf , Iraq , ella.talib1@gmail.com
2- Faculty of Sciences, University of Kufa, Najaf , Iraq
2- Faculty of Sciences, University of Kufa, Najaf , Iraq
Abstract: (1075 Views)
Introduction: Breast cancer is the most common malignant tumor in women. P53 is the most frequently altered gene in breast cancer. This study aimed to evaluate the correlation of the immunohistochemical expression of P53 protein with age and histopathological variables in breast cancer patients.
Method: This cross-sectional study was conducted on 40 women with breast cancer referred to the Middle Euphrates Unit for Cancer Research, Najaf, Iraq, from January 2019 to April 2021. Pathologists from different diagnostic centers in Najaf province examined tumor histopathological characteristics, including histological type, grade of tumor, expression of the p53 protein, and ERBB2 (HER2/neu) on 40 blocks of paraffin-fixed breast tumor samples. The association between p53 expression and each of the other variables was assessed using the chi-square test.
Results: Most participants were in the age group 50-59 years (47.5%). The highest percentage of the p53 protein positivity was found in the age group ≥50 years (75%), tumor grade 2, 3 (50%, 33.3%), invasive ductal carcinoma (91.7%), and HER2-negative group (75%). The expression of p53 was not significantly correlated to any of the investigated variables.
Conclusion: It may be possible to use p53 immunohistochemical expression to predict treatment response or disease progression in breast cancer. However, the value of examining p53 in the follow-up periods of patients or using it in treatment protocols requires more studies.
Method: This cross-sectional study was conducted on 40 women with breast cancer referred to the Middle Euphrates Unit for Cancer Research, Najaf, Iraq, from January 2019 to April 2021. Pathologists from different diagnostic centers in Najaf province examined tumor histopathological characteristics, including histological type, grade of tumor, expression of the p53 protein, and ERBB2 (HER2/neu) on 40 blocks of paraffin-fixed breast tumor samples. The association between p53 expression and each of the other variables was assessed using the chi-square test.
Results: Most participants were in the age group 50-59 years (47.5%). The highest percentage of the p53 protein positivity was found in the age group ≥50 years (75%), tumor grade 2, 3 (50%, 33.3%), invasive ductal carcinoma (91.7%), and HER2-negative group (75%). The expression of p53 was not significantly correlated to any of the investigated variables.
Conclusion: It may be possible to use p53 immunohistochemical expression to predict treatment response or disease progression in breast cancer. However, the value of examining p53 in the follow-up periods of patients or using it in treatment protocols requires more studies.
Type of Study: Research |
Received: 2022/02/12 | Accepted: 2022/10/4 | Published: 2022/10/18
Received: 2022/02/12 | Accepted: 2022/10/4 | Published: 2022/10/18
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
